Volume 6.47 | Dec 4

Cord Blood News 6.47 December 4, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
A Decline in Wnt3a Signaling Is Necessary for Mesenchymal Stem Cells to Proceed to Replicative Senescence
Scientists show that the expression levels of canonical Wnt families decrease as umbilical cord blood-derived mesenchymal stem cells age during subculture. [Stem Cells Dev] Abstract
Technical Bulletin: Assays For Cord Blood
PUBLICATIONS (Ranked by impact factor of the journal)
Acute GvHD in Patients Receiving IL-15/4-1BBL Activated NK Cells following T Cell Depleted Stem Cell Transplantation
In an effort to amplify the beneficial effects of NK cells post-HSCT, researchers conducted a first-in-human trial of adoptive transfer of donor-derived IL-15/4-1BBL activated NK cells following HLA-matched, T cell depleted non-myeloablative PBSCT in children and young adults with ultra-high risk solid tumors. [Blood] Abstract

A Survey on Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia
Investigators analyzed the outcome of 229 adult patients with de novo acute leukemia, who received an unmanipulated haploidentical transplant as their first allogeneic hematopoietic stem cell transplantation. [Leukemia] Abstract

Intranasal versus Intraperitoneal Delivery of Human Umbilical Cord Tissue-Derived Cultured Mesenchymal Stromal Cells in a Murine Model of Neonatal Lung Injury
Scientists studied the morphologic and functional effects of intranasal versus intraperitoneal mesenchymal stromal cell administration in a rodent model of neonatal lung injury. [Am J Pathol] Abstract

Umbilical Cord Mesenchymal Stromal Cells Affected by Gestational Diabetes Mellitus Display Premature Aging and Mitochondrial Dysfunction
Scientists compared the basic properties of human umbilical cord mesenchymal stromal cells obtained from gestational diabetes mellitus patients and normal pregnant women. [Stem Cells Dev] Abstract

Post-Thaw Non-Cultured and Post-Thaw Cultured Equine Cord Blood Mesenchymal Stromal Cells Equally Suppress Lymphocyte Proliferation In Vitro
Investigators hypothesized that in vitro there is no difference in lymphocyte suppression potential between quick-thawed cryopreserved equine cord blood mesenchymal stromal cells (MSC) immediately included in mixed lymphocyte reaction (MLR) and the same MSC allowed post-thaw culture time prior to inclusion in MLR. [PLoS One] Full Article

Treosulfan Based Reduced Toxicity Conditioning followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis
Researchers report 14 patients affected by myelofibrosis with a median age of 57 years receiving a treosulfan-fludarabine based reduced toxicity conditioning. Patients received a stem cell transplantation from an HLA identical or matched unrelated donor. [Hematol Oncol] Abstract

Therapeutic Effect of Human Umbilical Cord Mesenchymal Stem Cells Modified by Angiotensin-Converting Enzyme 2 Gene on Bleomycin-Induced Lung Fibrosis Injury
Investigators evaluated the therapeutic effects of human umbilical cord mesenchymal stem cells in the presence of angiotensinconverting enzyme 2 gene on bleomycin induced lung injury and pulmonary fibrosis in mice. [Mol Med Rep] Abstract | Download Full Article

Free Poster: Quick Reference for Mouse Immune Cell Frequencies and Percentages
Do HLA-E Polymorphisms Influence Graft-versus-Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation?
The role of HLA-E and its polymorphisms in hematopoietic stem cell transplantation outcomes such as graft-versus-host disease, transplant-related mortality as well as improved survival has been published by a number of groups. [Exp Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Unum Therapeutics Announces Start of First Phase I Clinical Trial of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Unum Therapeutics announced that recruitment has begun in the first clinical trial of the ATTCK20 therapy. The Phase I study will examine the feasibility, safety and potential efficacy of infusing the ATTCK20 combination therapy in patients with B-cell malignancies and persistent disease following standard therapy. [Unum Therapeutics] Press Release

CPRIT Awards UTSW Faculty $22.5 Million for Recruitment and Research in Liver Cancer, Leukemia, and Immunotherapy
UT Southwestern Medical Center faculty was awarded seven grants totaling more than $22 million from the Cancer Prevention and Research Institute of Texas (CPRIT) for investigations into leukemia, liver cancer, and immunotherapy, as well as to recruit new faculty. [UT Southwestern Medical Center] Press Release

Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Actinium Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. [Actinium Pharmaceuticals, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW International Society for Stem Cell Research (ISSCR) 13th Annual Meeting
June 24-27, 2015
Stockholm, Sweden

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Positions – Stem Cells and Bioengineering (Queensland University of Technology)

NEW Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

PhD Student – Department of Hematopoiesis (Sanquin)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Molecular Mechanisms Regulating Human Hematopoietic Specification (Washington University School of Medicine)

Quality Improvement Coordinator – Regenerative Medicine (The University of Texas Health Science Center at Houston)

Cord Tissue Processing Technician (Cord Blood Registry)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us